SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Cabaletta Bio Reports Third-Quarter 2026 Results, Updates RESET-Myositis Timeline

Cabaletta Bio said RESET-Myositis registrational adult topline results are anticipated in 2H27, with a BLA submission in 1Q28.

CABA

Story updates

12:32:59 PM UTC
SquawkNews
Cabaletta Bio reported $299.4M in cash as of September 30, 2026, and said its operational runway extends into 1Q28. It expects RESET-Myositis topline results in 2H27 and plans a BLA submission in 1Q28.Material DetailsContext by AI AnalystThis is a mid-cycle clinical-stage update, with the company a…

Related stories